On April 2, 2026, the FDA sent a warning letter to Purolea Cosmetics Lab, a small homeopathic drug manufacturer in Livonia, Michigan that made over-the-counter products marketed to treat shingles and genital herpes. Buried inside a routine list of manufacturing violations was something regulators had never put in writing before: a dedicated section titled “Inappropriate Use of Artificial Intelligence in Pharmaceutical Manufacturing.” It is the first FDA enforcement action to explicitly call out AI misuse, and its reasoning has implications well beyond one small cosmetics lab.
A small company, a big regulatory first
Purolea’s problems started with an FDA inspection in October 2025, after which the company stopped drug production entirely. The inspection turned up a litany of conventional manufacturing failures: insects and foreign material found in production areas, no microbiological testing performed on finished products, no identity or purity testing of incoming raw materials, and unapproved new drug claims printed directly on product labels. None of that was novel territory for an FDA warning letter. What made this one different was how Purolea had been generating its compliance paperwork.
How AI got the company into trouble
Investigators found that Purolea had used AI agents to generate drug product specifications, standard operating procedures, and master production and control records — the core documents that govern how a regulated drug is supposed to be manufactured — without meaningful human review before those documents entered the company’s quality system and guided actual production. In other words, an AI tool wrote the rulebook the factory followed, and nobody with regulatory authority checked whether the rulebook was accurate or compliant before it went into use.
The company’s defense, and why the FDA rejected it
When cited for missing required process validation steps, Purolea reportedly argued that the AI tool it used had never told the company such validation was legally required — an attempt to shift blame onto the software itself. The FDA rejected that argument outright. The agency’s letter made clear that “if you use AI as an aid in document creation, you must review the AI” generated output to ensure it is accurate and meets current good manufacturing practice requirements. Crucially, the FDA didn’t invent a new rule to make this point — it applied an existing regulation, 21 CFR 211.22(c), which establishes that a company’s quality unit bears accountability for its records, regardless of whether a human or a machine drafted them first.
Echoes of an old fight over data integrity
Regulatory attorneys tracking the letter have drawn a direct parallel to how the FDA handled data integrity violations in the 2000s and 2010s, when manufacturers began relying more heavily on digital systems and electronic records, and the agency had to repeatedly clarify that automation didn’t dilute a company’s responsibility for what those systems produced. The AI warning letter follows the same logic: a tool can draft a document, but a named, accountable human still has to sign off on it before it governs a regulated process. That principle sounds obvious in the abstract, but Purolea’s case shows how easily it gets skipped in practice when a fast, convincing AI output creates a false sense that the work is already done.
Why this matters far beyond one cosmetics lab
Purolea is a minor player, but the warning letter’s real audience is every pharmaceutical and medical device manufacturer now experimenting with generative AI to draft the mountains of documentation FDA compliance requires — specifications, SOPs, validation protocols, batch records. Legal and quality-assurance advisors have flagged this letter as a signal that FDA field investigators are now actively looking for AI-generated content inside quality management systems during routine inspections, not just in dedicated AI/ML software submissions. Companies that assumed AI-drafted paperwork was a low-risk shortcut, provided the output looked professional, now have written confirmation that the agency disagrees.
What companies need to do differently now
The letter requires that if Purolea resumes manufacturing using AI tools, every AI-generated output and recommendation must undergo documented review and formal clearance by an authorized quality-unit representative before implementation — not a quick skim, but a recorded, auditable sign-off. Compliance consultants are already advising clients to build that same documented-review step into any workflow where generative AI touches a regulated document, treating it as a new mandatory checkpoint rather than an optional best practice. For an industry racing to use AI to speed up everything from clinical trial paperwork to manufacturing records, Purolea’s warning letter is a small case with an outsized message: the FDA will hold the human, not the algorithm, accountable when something goes wrong.
